In Vitro activities of synthetic host defense propeptides processed by neutrophil elastase against cystic fibrosis pathogens

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 5, 2011, Pages 2487-2489

  Desgranges, Stephane ^a   Le Prieult, Florie ^a   Daly, Alan ^a   Lydon, Jennifer ^a   Brennan, Marian ^a   Rai, Dilip K ^c   Subasinghage, Anusha P ^c   Hewage, Chandralal M ^c   Cryan, Sally Ann ^a   Greene, Catherine ^b   McElvaney, Noel G ^b   Smyth, Timothy P ^d   Fitzgerald Hughes, Deirdre ^a   Humphreys, Hilary ^a,b   Devocelle, Marc ^a  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^b BEAUMONT HOSPITAL   (Ireland)

^c UNIVERSITY COLLEGE DUBLIN   (Ireland)

^d UNIVERSITY OF LIMERICK   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

LEUKOCYTE ELASTASE; POLYPEPTIDE ANTIBIOTIC AGENT;

ANTIMICROBIAL ACTIVITY; ARTICLE; CYSTIC FIBROSIS; DISEASE ASSOCIATION; ENZYME ACTIVITY; HEMOLYSIS; HOST RESISTANCE; IN VITRO STUDY; LUNG INFECTION; NONHUMAN; PATHOGENESIS; PNEUMONIA; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS;

CYSTIC FIBROSIS; HEMOLYSIS; HUMANS; LEUKOCYTE ELASTASE; PEPTIDES; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS;

EID: 79955540343     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01384-10     Document Type: Article

References (26)

1. Bergsson, G., et al. 2009. LL-37 complexation with glycosaminoglycans in cystic fibrosis lungs inhibits antimicrobial activity, which can be restored by hypertonic saline. J. Immunol. 183:543-551.
2. Bode, W., E. Meyer, Jr., and J. C. Powers. 1989. Human leukocyte and porcine pancreatic elastase: X-ray crystal structures, mechanism, substrate specificity, and mechanism-based inhibitors. Biochemistry 28:1951-1963.
3. Bowdish, D. M., D. J. Davidson, and R. E. W. Hancock. 2005. A re-evaluation of the role of host defence peptides in mammalian immunity. Curr. Protein Pept. Sci. 6:35-51.
4. Chen, H.-C., J. H. Brown, J. L. Morell, and C. M. Huang. 1988. Synthetic magainin analogues with improved antimicrobial activity. FEBS Lett. 2:462-466.
5. Chen, Y. X., et al. 2006. Comparison of biophysical and biologic properties of alpha-helical enantiomeric antimicrobial peptides. Chem. Biol. Drug Des. 67:162-173.
6. Finlay, B. B., and R. E. W. Hancock. 2004. Can innate immunity be enhanced to treat microbial infections? Nat. Rev. Microbiol. 2:497-504.
7. Greene, C. M., et al. 2005. TLR-induced inflammation in cystic fibrosis and non-cystic fibrosis airway epithelial cells. J. Immunol. 174:1638-1646.
8. Hancock, R. E. W. 2001. Cationic peptides: effectors in innate immunity and novel antimicrobials. Lancet Infect. Dis. 1:156-164.
9. Hancock, R. E. W., and G. Diamond. 2000. The role of cationic antimicrobial peptides in innate host defences. Trends Microbiol. 8:402-410.
10. Hancock, R. E. W., and H.-G. Sahl. 2006. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat. Biotechnol. 24: 1551-1557.
11. Hyde, C., T. Johnson, D. Owen, M. Quibell, and R. C. Sheppard. 1994. Some 'difficult sequences' made easy. A study of interchain association in solid-phase peptide synthesis. Int. J. Pept. Protein Res. 43:431-440.
12. Jiang, Z. Q., et al. 2008. Effects of net charge and the number of positively charged residues on the biological activity of amphipathic alpha-helical cationic antimicrobial peptides. Biopolymers 90:369-383.
13. Kelly, E., C. M. Greene, and N. G. McElvaney. 2008. Targeting neutrophil elastase in cystic fibrosis. Expert Opin. Ther. Targets 12:145-157.
14. Merrifield, R. B. 1986. Solid phase synthesis. Science 232:341-347.
15. Peschel, A., and H.-G. Sahl. 2006. The co-evolution of host cationic antimicrobial peptides and microbial resistance. Nat. Rev. Microbiol. 4:529-536.
16. Pham, C. T. N. 2006. Neutrophil serine proteases: specific regulators of inflammation. Nat. Rev. Immunol. 6:541-550.
17. Poncz, L., N. Jentoft, M.-C. D. Ho, and D. G. Dearborn. 1988. Kinetics of proteolysis of hog gastric mucin by human neutrophil elastase and by Pseudomonas aeruginosa elastase. Infect. Immun. 56:703-704.
18. Rautio, J., et al. 2008. Prodrugs: design and clinical applications. Nat. Rev. Drug Discov. 7:255-270.
19. Rowe, S. M., S. Miller, and E. J. Sorscher. 2005. Cystic fibrosis. N. Engl. J. Med. 352:1992-2001.
20. Shin, S. Y., J. H. Kang, and K.-S. Hahm. 1999. Structure-antibacterial, antitumor and hemolytic activity relationships of cecropin A-magainin 2 and cecropin A-melittin hybrid peptides. J. Pept. Res. 53:82-90.
21. Shin, S. Y., et al. 2002. Salt resistance and synergistic effect with vancomycin of α-helical antimicrobial peptide P18. Biochem. Biophys. Res. Commun. 290:558-562.
22. Tossi, A., L. Sandri, and A. Giangaspero. 2000. Amphipathic, alpha-helical antimicrobial peptides. Biopolymers 55:4-30.
23. Wade, D., et al. 1990. All-D amino acid-containing channel-forming antibiotic peptides. Proc. Natl. Acad. Sci. U. S. A. 87:4761-4765.
24. Yeaman, M. R., and N. Y. Yount. 2007. Unifying themes in host defence effector polypeptides. Nat. Rev. Microbiol. 5:727-740.
25. Zanetti, M. 2005. The role of cathelicidins in the innate host defenses of mammals. Curr. Issues Mol. Biol. 7:179-196.
26. Zasloff, M. 2002. Antimicrobial peptides of multicellular organisms. Nature 415:389-395. (Pubitemid 34100944)